These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16171861)

  • 1. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
    Seshadri T; Hourigan MJ; Wolf M; Mollee PN; Seymour JF
    Leuk Res; 2006 Apr; 30(4):483-5. PubMed ID: 16171861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
    Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
    Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
    Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
    Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
    Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
    Xu W; Li JY; Qian SX; Wu HX; Lu H; Chen LJ; Zhang SJ; Lu RL; Sheng RL
    Leuk Res; 2008 Jun; 32(6):930-5. PubMed ID: 18061665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.
    Dann EJ; Epelbaum R; Avivi I; Ben Shahar M; Haim N; Rowe JM; Blumenfeld Z
    Hum Reprod; 2005 Aug; 20(8):2247-9. PubMed ID: 15817583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
    Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
    Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive paresthesia and weakness after intrathecal chemotherapy.
    Marshall R; Gupta ND; Palacios E; Neitzschman HR
    J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
    J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    O'Brien S; Thomas DA; Ravandi F; Faderl S; Pierce S; Kantarjian H
    Cancer; 2008 Oct; 113(8):2097-101. PubMed ID: 18720356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An adult case of precursor B cell lymphoblastic lymphoma extending from right neck to upper cervical spinal region].
    Nishihara M; Kudo H; Mizuno I; Taomoto K; Kohmura E
    No Shinkei Geka; 2005 Nov; 33(11):1107-11. PubMed ID: 16277225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
    Alduaij A; Butera JN; Treaba D; Castillo J
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):480-3. PubMed ID: 21156467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
    Thomas D; O'Brien S; Faderl S; Ravandi F; Jabbour E; Pierce S; Cortes J; Kantarjian H
    Cancer; 2010 Oct; 116(19):4580-9. PubMed ID: 20572037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
    Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
    Keane C; Gibbs S; Seymour JF; Mills AK; Grimmett K; Van Kuilenberg R; Saal R; Gill D; Prince HM; Marlton P; Mollee P
    Hematol Oncol; 2006 Sep; 24(3):159-63. PubMed ID: 16775841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.